Insider Selling: ACADIA Pharmaceuticals CMO Sells 35,965 Shares of Stock (ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD) CMO Roger Mills sold 35,965 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $25.01, for a total value of $899,484.65. Following the completion of the sale, the chief marketing officer now directly owns 15,775 shares of the company’s stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on ACAD shares. Analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from $20.00 to $23.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note to investors on Wednesday, August 7th. They now have a $26.00 price target on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from $15.00 to $24.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock.
One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.43.
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 1.51% on Friday, hitting $24.87. The stock had a trading volume of 3,626,051 shares. ACADIA Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $24.50. The stock’s 50-day moving average is $21.10 and its 200-day moving average is $15.50. The company’s market cap is $2.208 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The company had revenue of $451.00 million for the quarter, compared to the consensus estimate of $0.45 million. Analysts expect that ACADIA Pharmaceuticals will post $-0.44 EPS for the current fiscal year.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.